Ph3 Study of Sonrotoclax plus Anti-CD20 in patients with chronic/small Lymphocytic Leukemia/Lymph
Phase III Clinical Trial
BGB-11417-303/CLL-RR1 / A Phase 3 Randomized Open-Label Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma